Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Rapidly progressive glomerulonephritis due to coexistent anti-glomerular basement membrane disease and fibrillary glomerulonephritis.

Cheungpasitporn W, Zacharek CC, Fervenza FC, Cornell LD, Sethi S, Herrera Hernandez LP, Nasr SH, Alexander MP.

Clin Kidney J. 2016 Feb;9(1):97-101. doi: 10.1093/ckj/sfv126. Epub 2015 Nov 30.

2.

Histiocytic glomerulopathy associated with macrophage activation syndrome.

Eirin A, Irazabal MV, Fervenza FC, Sethi S.

Clin Kidney J. 2015 Apr;8(2):157-60. doi: 10.1093/ckj/sfv010. Epub 2015 Feb 17.

3.

Anti-phospholipase A₂ receptor antibodies in recurrent membranous nephropathy.

Kattah A, Ayalon R, Beck LH Jr, Sethi S, Sandor DG, Cosio FG, Gandhi MJ, Lorenz EC, Salant DJ, Fervenza FC.

Am J Transplant. 2015 May;15(5):1349-59. doi: 10.1111/ajt.13133. Epub 2015 Mar 12.

4.

Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations.

Sethi S, Zand L, Nasr SH, Glassock RJ, Fervenza FC.

Clin Kidney J. 2014 Dec;7(6):531-7. doi: 10.1093/ckj/sfu100. Epub 2014 Sep 28.

5.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.

Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Tchao NK, Ikle D, Jepson B, Brunetta P, Fervenza FC; Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group.

J Am Soc Nephrol. 2015 Apr;26(4):976-85. doi: 10.1681/ASN.2014010046. Epub 2014 Nov 7.

6.

Circulating complement levels and C3 glomerulopathy.

Fervenza FC, Sethi S.

Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1829-31. doi: 10.2215/CJN.09620914. Epub 2014 Oct 23. No abstract available.

7.

IgD heavy-chain deposition disease: detection by laser microdissection and mass spectrometry.

Royal V, Quint P, Leblanc M, LeBlanc R, Duncanson GF, Perrizo RL, Fervenza FC, Kurtin P, Sethi S.

J Am Soc Nephrol. 2015 Apr;26(4):784-90. doi: 10.1681/ASN.2014050481. Epub 2014 Sep 5.

8.

Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.

Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Iklé D, Villarreal M, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.

Arthritis Rheumatol. 2014 Nov;66(11):3151-9. doi: 10.1002/art.38788.

9.

A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy.

Hladunewich MA, Cattran D, Beck LH, Odutayo A, Sethi S, Ayalon R, Leung N, Reich H, Fervenza FC.

Nephrol Dial Transplant. 2014 Aug;29(8):1570-7. doi: 10.1093/ndt/gfu069. Epub 2014 Apr 8.

10.

Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis.

Clain JM, Cartin-Ceba R, Fervenza FC, Specks U.

Ther Adv Musculoskelet Dis. 2014 Apr;6(2):58-74. doi: 10.1177/1759720X13516239. Review.

11.

American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis.

Fervenza FC, Perazella MA, Choi MJ.

Clin J Am Soc Nephrol. 2014 May;9(5):987-96. doi: 10.2215/CJN.11571113. Epub 2014 Feb 27.

12.

Clinical findings, pathology, and outcomes of C3GN after kidney transplantation.

Zand L, Lorenz EC, Cosio FG, Fervenza FC, Nasr SH, Gandhi MJ, Smith RJ, Sethi S.

J Am Soc Nephrol. 2014 May;25(5):1110-7. doi: 10.1681/ASN.2013070715. Epub 2013 Dec 19.

13.

C3 glomerulopathy: consensus report.

Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT.

Kidney Int. 2013 Dec;84(6):1079-89. doi: 10.1038/ki.2013.377. Epub 2013 Oct 30.

14.

A patient with nephrotic-range proteinuria and focal global glomerulosclerosis.

Fervenza FC.

Clin J Am Soc Nephrol. 2013 Nov;8(11):1979-87. doi: 10.2215/CJN.03400313. Epub 2013 Jul 25.

15.

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Iklé D, Jepson B, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.

Arthritis Rheum. 2013 Sep;65(9):2441-9. doi: 10.1002/art.38044.

16.

Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.

Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H.

Transplantation. 2013 Aug 27;96(4):394-9. doi: 10.1097/TP.0b013e3182977ab1.

17.

C3 glomerulonephritis associated with monoclonal gammopathy: a case series.

Zand L, Kattah A, Fervenza FC, Smith RJ, Nasr SH, Zhang Y, Vrana JA, Leung N, Cornell LD, Sethi S.

Am J Kidney Dis. 2013 Sep;62(3):506-14. doi: 10.1053/j.ajkd.2013.02.370. Epub 2013 Apr 26.

18.

American Society of Nephrology Quiz and Questionnaire 2012: glomerulonephritis.

Fervenza FC, Glassock RJ, Bleyer AJ.

Clin J Am Soc Nephrol. 2013 Aug;8(8):1460-5. doi: 10.2215/CJN.00440113. Epub 2013 Mar 28.

19.

Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy.

Sethi S, Theis JD, Vrana JA, Fervenza FC, Sethi A, Qian Q, Quint P, Leung N, Dogan A, Nasr SH.

Clin J Am Soc Nephrol. 2013 Jun;8(6):915-21. doi: 10.2215/CJN.07030712. Epub 2013 Feb 14.

20.

Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach.

Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PX, Barisoni L, Sampson MG, Kopp JB, Lemley KV, Nelson PJ, Lienczewski CC, Adler SG, Appel GB, Cattran DC, Choi MJ, Contreras G, Dell KM, Fervenza FC, Gibson KL, Greenbaum LA, Hernandez JD, Hewitt SM, Hingorani SR, Hladunewich M, Hogan MC, Hogan SL, Kaskel FJ, Lieske JC, Meyers KE, Nachman PH, Nast CC, Neu AM, Reich HN, Sedor JR, Sethna CB, Trachtman H, Tuttle KR, Zhdanova O, Zilleruelo GE, Kretzler M.

Kidney Int. 2013 Apr;83(4):749-56. doi: 10.1038/ki.2012.428. Epub 2013 Jan 16.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk